U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H17N3S
Molecular Weight 211.327
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRAMIPEXOLE

SMILES

CCCN[C@H]1CCC2=C(C1)SC(N)=N2

InChI

InChIKey=FASDKYOPVNHBLU-ZETCQYMHSA-N
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1

HIDE SMILES / InChI
Molecular Formula C10H17N3S
Molecular Weight 211.327
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf

Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. Pramipexole is used for the treatment of signs and symptoms of idiopathic Parkinson's disease.

CNS Activity

Originator

Approval Year

1997
172
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 1.5 nM [EC50]
Agonist
2678
 27.0 nM [EC50]
Agonist
2678
 15.0 nM [EC50]
Inhibitor
8297
 4.81 µM [IC50]
Inhibitor
8297
 5.37 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

1997
Primary
Approved
8429
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.268 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20110012
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.29 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20110012
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.2 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20110012
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Disc. AE: Hallucination, Hypotension...
AEs leading to
discontinuation/dose reduction:
Hallucination (1.3%)
Hypotension (0.5%)
Peripheral edema (0.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
Disc. AE: Hallucinations, Sleepiness...
AEs leading to
discontinuation/dose reduction:
Hallucinations (4.3%)
Sleepiness (3%)
Dizziness (2.5%)
Memory loss (1.2%)
Paranoia (0.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
DLT: Drowsiness, Muscle spasms...
Dose limiting toxicities:
Drowsiness (3.6%)
Muscle spasms (1.8%)
Insomnia (1.8%)
Vertigo (1.8%)
Ankle swelling (1.8%)
Hallucination (3.6%)
Nausea (1.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Disc. AE: Nausea, Hallucination...
AEs leading to
discontinuation/dose reduction:
Nausea (0.6%)
Hallucination (1%)
Peripheral edema (0.8%)
Abdominal pain upper (0.6%)
Myocardial infarction (0.6%)
Pneumonia (0.6%)
Vomiting (0.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
AEs

AEs

AESignificanceDosePopulation
Hypotension 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Peripheral edema 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Hallucination 1.3%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 61.6
n = 391
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 61.6
Sex: M+F
Population Size: 391
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Paranoia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
Memory loss 1.2%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
Dizziness 2.5%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
Sleepiness 3%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
Hallucinations 4.3%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
unhealthy, 62.7
n = 163
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.7
Sex: M+F
Population Size: 163
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Page: p.727
Ankle swelling 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
Insomnia 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
Muscle spasms 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
Nausea 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
Vertigo 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
Drowsiness 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
Hallucination 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
unhealthy, 62.8
n = 55
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 62.8
Sex: M+F
Population Size: 55
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Page: p.128
Abdominal pain upper 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Myocardial infarction 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Nausea 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Pneumonia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Vomiting 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Peripheral edema 0.8%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Hallucination 1%
Disc. AE
1.5 mg 3 times / day multiple, oral (max)
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
unhealthy, 63
n = 511
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 63
Sex: M+F
Population Size: 511
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Page: p.740
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8356
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8356
ChemicalBook
CB0486178
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0486178
MolPort
MolPort-003-849-957
https://www.molport.com/shop/molecule-link/MolPort-003-849-957
Selleck Chemicals
Pramipexole-Mirapex
http://www.selleckchem.com/products/Pramipexole-Mirapex.html
ZINC
ZINC000003781664
http://zinc15.docking.org/substances/ZINC000003781664
eMolecules
6843675
https://www.emolecules.com/cgi-bin/more?vid=6843675
PubMed

PubMed

TitleDatePubMed
Does combined treatment with novel antidepressants and a dopamine D3 receptor agonist reproduce cocaine discrimination in rats?
2001 Nov-Dec
Locomotor hypoactivity and motor disturbances--behavioral effects induced by intracerebellar microinjections of dopaminergic DA-D2/D3 receptor agonists.
2001 Sep-Oct
DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease.
2002
Choosing the right dopamine agonist for patients with Parkinson's disease.
2002
'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?
2002
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
2002
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
2002 Apr 3
Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
2002 Aug
Two advances in the management of Parkinson disease.
2002 Aug
[Rapid-eye-movement sleep disorders in Parkinson's disease].
2002 Feb
Pramipexole for depression.
2002 Feb
Restless legs syndrome: treatment with dopaminergic agents.
2002 Feb 26
Long-term studies of dopamine agonists.
2002 Feb 26
[Rhabdomyolysis as a complication of Parkinson's disease].
2002 Jan-Feb
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
2002 Jun
[Multiple latency test in a patient with episodes of sleep induced by pergolide].
2002 Jun 16-30
Sleep attacks in patients taking dopamine agonists: review.
2002 Jun 22
A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole.
2002 May
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
2002 May 14
Do dopamine agonists or levodopa modify Parkinson's disease progression?
2002 Nov
Dopamine agonists and neuroprotection in Parkinson's disease.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
Dopamine agonist monotherapy in Parkinson's disease.
2002 Nov 30
Neuroprotection in idiopathic Parkinson's disease.
2002 Oct
Pramipexole in treatment-resistant depression: a 16-week naturalistic study.
2002 Oct
An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease.
2002 Oct
Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice.
2002 Oct
Effect of daily dosing duration of direct and indirect dopamine receptor agonists: cocaine cross-tolerance following chronic regimens.
2002 Oct
Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
2002 Oct-Dec
Combination of two different dopamine agonists in the management of Parkinson's disease.
2002 Sep
Review: selegiline improves symptoms and levodopa is better than pramipexole for motor function in untreated Parkinson disease.
2002 Sep-Oct
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
2003
Advances in the pharmacological management of Parkinson disease.
2003
Inhibitory effects of D2 agonists by striatal injection on excessive release of dopamine and hyperactivity induced by Bay K 8644 in rats.
2003
Dopamine agonists induce episodes of irresistible daytime sleepiness.
2003
Current status of Parkinson's disease treatment in Korea.
2003 Aug
Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.
2003 Aug 15
Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
2003 Aug 8
Piribedil-induced sleep attacks in Parkinson's disease.
2003 Feb
Slowing Parkinson's disease progression: recent dopamine agonist trials.
2003 Feb 11
Loss of color vision during long-term treatment with pramipexole.
2003 Jan
Sleepwalking and sleep terrors in prepubertal children: what triggers them?
2003 Jan
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.
2003 Jul
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
2003 Jul
Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
2003 Jul
Efficacy, safety and cost of new drugs acting on the central nervous system.
2003 May
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
2003 May
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
2003 Nov
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
2003 Sep
Patents

Patents

JP2006505569A
69
JP2007514770A
75
JP2011526251A
112
JP2012500800A
9
JPH03170425A
3

Sample Use Guides

In Vivo Use Guide
Dosages should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days.
Route of Administration: Oral
In Vitro Use Guide
Pramipexole suppressed H2O2-induced ARPE-19 cell death in vitro at concentrations of 10(-6) M or higher.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:44:22 GMT 2023
Edited
by admin
on Fri Dec 15 15:44:22 GMT 2023
Record UNII
83619PEU5T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRAMIPEXOLE
INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
U-98528E
Code English
SUD-919CL2Y
Code English
SUD919CL2Y
Code English
PRAMIPEXOLE [USAN]
Common Name English
Pramipexole [WHO-DD]
Common Name English
NSC-760426
Code English
pramipexole [INN]
Common Name English
CTC-501
Code English
PRAMIPEXOLE [VANDF]
Common Name English
PRAMIPEXOLE [MI]
Common Name English
PRAMIPEXOL
Common Name English
Classification Tree Code System Code
WHO-VATC QN04BC05
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
LIVERTOX NBK547968
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
NDF-RT N0000000117
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
FDA ORPHAN DRUG 252007
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
NCI_THESAURUS C265
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
WHO-ATC N04BC05
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
NDF-RT N0000175768
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
Code System Code Type Description
SMS_ID
100000085495
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
PUBCHEM
119570
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
NSC
760426
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
DRUG BANK
DB00413
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
CAS
104632-26-0
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
WIKIPEDIA
PRAMIPEXOLE
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
DRUG CENTRAL
2233
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
DAILYMED
83619PEU5T
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
NCI_THESAURUS
C66456
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
USAN
HH-63
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
RXCUI
746741
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY RxNorm
LACTMED
Pramipexole
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
EPA CompTox
DTXSID6023496
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
IUPHAR
953
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
FDA UNII
83619PEU5T
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
INN
6227
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
HSDB
8253
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
CHEBI
8356
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
MESH
C061333
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
MERCK INDEX
m9095
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY Merck Index
EVMPD
SUB09990MIG
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL301265
Created by admin on Fri Dec 15 15:44:22 GMT 2023 , Edited by admin on Fri Dec 15 15:44:22 GMT 2023
PRIMARY
Related Record Type Details
Structure of PRAMIPEXOLE DIHYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of PRAMIPEXOLE DIHYDROCHLORIDE ANHYDROUS
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
D(4) DOPAMINE RECEPTOR
TARGET -> AGONIST
D(3) DOPAMINE RECEPTOR
TARGET -> AGONIST
MATE-2
TRANSPORTER -> INHIBITOR
D(2) DOPAMINE RECEPTOR
TARGET -> AGONIST
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of PRAMIPEXOLE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966